Neurent Medical Secures €25M Debt Facility From Claret Capital
Image
Galway, Ireland – – September 13, 2026 -- Neurent Medical has secured a €25 million growth debt financing facility from Claret Capital Partners to accelerate commercial expansion of its NEUROMARK® System for chronic rhinitis treatment.
Debt facility follows €62.5 million Series C round completed earlier in 2026
The new €25 million facility builds on Neurent Medical's €62.5 million Series C financing round, which closed earlier this year. The combined capital reinforces the company's position in minimally invasive treatments for chronic inflammatory sinonasal diseases.